QGEN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

528.80M

+1.46%

0.596

-2.32%

510.08M

+5.51%

0.579

+5.28%

557.97M

+4.58%

0.643

+7.1%

Estimates Revision

The market is revising Downward the revenue expectations for Qiagen N.V. (QGEN) for FY2025, with the revenue forecasts being adjusted by -0.19% over the past three months. During the same period, the stock price has changed by -0.51%.

Revenue Estimates for FY2025

Revise Downward

-0.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.67%

In Past 3 Month

Stock Price

Go Down

-0.51%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 49.34 USD with a low forecast of 45.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

5 Hold

0 Sell

Moderate Buy

Current: 45.160

Low

45.00

Averages

49.34

High

55.00

Current: 45.160

Low

45.00

Averages

49.34

High

55.00

Barclays

NULL

Overweight

maintain

$53 -> $55

2025-12-15

New

Reason

Barclays

Price Target

$53 -> $55

2025-12-15

New

maintain

NULL

Overweight

Reason

Barclays raised the firm's price target on Qiagen to $55 from $53 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Citi

Patrick Donnelly

Buy -> Neutral

downgrade

$55 -> $50

2025-12-11

New

Reason

Citi

Patrick Donnelly

Price Target

$55 -> $50

2025-12-11

New

downgrade

Buy -> Neutral

Reason

Citi analyst Patrick Donnelly downgraded Qiagen to Neutral from Buy with a price target of $50, down from $55. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. It sees Qiagen shares remaining in a trading range given its challenging comparisons and margin dilution from recent acquisitions.

Berenberg

Harry Gillis

Buy

downgrade

2025-11-12

Reason

Berenberg

Harry Gillis

Price Target

2025-11-12

downgrade

Buy

Reason

Berenberg analyst Harry Gillis lowered the firm's price target on Qiagen to EUR 46 from EUR 50 and keeps a Buy rating on the shares.

TD Cowen

Hold

downgrade

$50 -> $48

2025-11-10

Reason

TD Cowen

Price Target

$50 -> $48

2025-11-10

downgrade

Hold

Reason

TD Cowen lowered the firm's price target on Qiagen to $48 from $50 and keeps a Hold rating on the shares. The firm updated its model as its Q3 report reflected solid trends while the Q4 and 2026 outlook were drags.

Baird

Outperform

NULL

downgrade

$49 -> $46

2025-11-06

Reason

Baird

Price Target

$49 -> $46

2025-11-06

downgrade

Outperform

NULL

Reason

Baird lowered the firm's price target on Qiagen to $46 from $49 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.

TD Cowen

Dan Brennan

Hold

maintain

$49 -> $52

2025-08-07

Reason

TD Cowen

Dan Brennan

Price Target

$49 -> $52

2025-08-07

maintain

Hold

Reason

TD Cowen analyst Dan Brennan raised the firm's price target on Qiagen to $52 from $49 and keeps a Hold rating on the shares. Following a modest beat and raise print, the conference call was largely "steady as she goes," with CEO/CFO discussing ongoing traction with the growth of their 5 Pillars enhanced via numerous R&D initiatives, navigating through tariff margin pressures, and a consistent capital allocation strategy, the firm notes.

Valuation Metrics

The current forward P/E ratio for Qiagen NV (QGEN.N) is 18.38, compared to its 5-year average forward P/E of 21.44. For a more detailed relative valuation and DCF analysis to assess Qiagen NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

21.44

Current PE

18.38

Overvalued PE

23.87

Undervalued PE

19.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.73

Current EV/EBITDA

12.96

Overvalued EV/EBITDA

16.25

Undervalued EV/EBITDA

13.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.10

Current PS

4.55

Overvalued PS

5.61

Undervalued PS

4.60

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 286.76% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

QGEN News & Events

Events Timeline

No data

News

9.0

11-26NASDAQ.COM

Recent Clinical Findings Support Hologic's Breast Cancer Innovations

5.0

11-21Yahoo Finance

Oracle Appoints Stephen Rusckowski to Its Board of Directors

5.0

11-13NASDAQ.COM

Hologic Broadens Availability of Genius Digital Diagnostics System in Europe

People Also Watch

Frequently Asked Questions

What is Qiagen NV (QGEN) stock price today?

The current price of QGEN is 45.16 USD — it has decreased -0.13 % in the last trading day.

What is Qiagen NV (QGEN)'s business?

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

What is the price predicton of QGEN Stock?

What is Qiagen NV (QGEN)'s revenue for the last quarter?

Qiagen NV revenue for the last quarter amounts to 532.58M USD, increased 6.12 % YoY.

What is Qiagen NV (QGEN)'s earnings per share (EPS) for the last quarter?

Qiagen NV. EPS for the last quarter amounts to 0.60 USD, increased 33.33 % YoY.

What changes have occurred in the market's expectations for Qiagen NV (QGEN)'s fundamentals?

How many employees does Qiagen NV (QGEN). have?

Qiagen NV (QGEN) has 5765 emplpoyees as of December 15 2025.

What is Qiagen NV (QGEN) market cap?

Today QGEN has the market capitalization of 9.81B USD.